Treating SCLC in the Relapsed/Refractory Setting: Giving Patients a Voice About Second-Line Therapy
| Overview / Abstract: |
SCLC is aggressive in nature with a high recurrence rate following initial treatment and a propensity to become resistant to conventional therapies. Early detection is critical, but many patients are diagnosed at an advanced stage where prognosis is poor. Progress in the second-line setting offers new hope for improving patient outcomes, but the rapid pace at which these advances are occurring present challenges for effectively integrating novel therapies into patient care. In fact, research shows that oncologists may not be offering second-line therapies to patients with SCLC despite good functional status. To help clinicians enhance their diagnostic-therapeutic paradigms for SCLC, this practice guide interweaves education and practical guidance for easy integration of the latest evidence-based strategies into daily clinical processes and workflows. |
|
Expiration |
Sep 15, 2025 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
|
Format |
Online, Webinar / Webcast / Video |
|
Credits / Hours |
1.0 |
|
Accreditation |
ACCME, MIPS QPP, ANCC |
|
Presenters / Authors / Faculty |
Firas Badin, MD, MBA Carl Gay, MD |
|
Sponsors / Supporters / Grant Providers |
Provided by The University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learning (ACHL). This program is supported by an independent medical education grant from Jazz Pharmaceuticals. |
|
Keywords / Search Terms |
ACHL ACHL CME, CE, ACCME, MIPS, CME, CE, MD Anderson, Jazz, small-cell lung cancer, SCLC, second-line, lung cancer, relapsed/refractory SCLC, oncologist, pathologist Free CE CME |
|